Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.

Inflammatory Bowel Diseases
Tamara Pérez-JeldresJesus Rivera-Nieves

Abstract

After 20 years of successful targeting of pro-inflammatory cytokines for the treatment of IBD, an alternative therapeutic strategy has emerged, based on several decades of advances in understanding the pathogenesis of IBD. The targeting of molecules involved in leukocyte traffic has recently become a safe and effective alternative. With 2 currently approved drugs (ie, natalizumab, vedolizumab) and several others in phase 3 trials (eg, etrolizumab, ozanimod, anti-MAdCAM-1), the blockade of trafficking molecules has firmly emerged as a new therapeutic era for IBD. We discuss the targets that have been explored in clinical trials: chemokines and its receptors (eg, IP10, CCR9), integrins (eg, natalizumab, AJM300, vedolizumab, and etrolizumab), and its endothelial ligands (MAdCAM-1, ICAM-1). We also discuss a distinct strategy that interferes with lymphocyte recirculation by blocking lymphocyte egress from lymph nodes (small molecule sphingosine-phosphate receptor [S1PR] agonists: fingolimod, ozanimod, etrasimod, amiselimod). Strategies on the horizon include additional small molecules, allosteric inhibitors that specifically bind to the active integrin form and nanovectors that allow for the use of RNA interference in the quest to ...Continue Reading

References

Jun 28, 2003·Trends in Molecular Medicine·Klaus Ley
Sep 3, 2003·Nature Reviews. Drug Discovery·Motomu Shimaoka, Timothy A Springer
Jul 20, 2004·Journal of Cellular Biochemistry·Hervé Le StunffSarah Spiegel
Feb 9, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jesús Rivera-NievesKlaus Ley
Mar 18, 2005·Annual Review of Immunology·Jason G Cyster
Aug 19, 2006·Inflammatory Bowel Diseases·Akira GotoYuji Hinoda
Feb 6, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Carolin DanielJuergen M Stein
Feb 14, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Bruce YacyshynEmil Chuang
May 7, 2008·Expert Review of Neurotherapeutics·Alejandro Horga, Xavier Montalban
Jun 5, 2008·Inflammatory Bowel Diseases·Jesús Rivera-NievesKlaus Ley
Aug 1, 2008·Inflammatory Bowel Diseases·Takayuki TomitaMamoru Watanabe
May 26, 2010·International Immunology·Yasuhiro MaedaKenji Chiba
Oct 5, 2010·Current Gastroenterology Reports·Brian S Sheridan, Leo Lefrançois
Apr 26, 2011·Journal of the American Academy of Dermatology·Namita KotharyGerald Dal Pan
Sep 29, 2011·Nature Cell Biology·Juha K RantalaJohanna Ivaska
Dec 30, 2011·Inflammopharmacology·Saskia Thomas, Daniel C Baumgart
Aug 24, 2012·Lancet·Daniel C Baumgart, William J Sandborn
Sep 6, 2012·Journal of Internal Medicine·J Marsal, W W Agace
Mar 26, 2013·PloS One·Satish KeshavUNKNOWN Prospective Randomized Oral-Therapy Evaluation in Crohn’s Disease Trial-1 PROTECT-1 Study Group
Apr 30, 2013·Current Drug Targets·Giorgos BamiasJesús Rivera-Nieves
Aug 24, 2013·The New England Journal of Medicine·Brian G FeaganUNKNOWN GEMINI 1 Study Group
Aug 24, 2013·The New England Journal of Medicine·William J SandbornUNKNOWN GEMINI 2 Study Group
Oct 1, 2013·Expert Opinion on Therapeutic Targets·Daniela Impellizzeri, Salvatore Cuzzocrea
Jan 24, 2014·Clinical and Experimental Immunology·N-E SerriariE Treiner
Feb 1, 2014·Alimentary Pharmacology & Therapeutics·T LobatónP Rutgeerts
Mar 25, 2014·Annual Review of Immunology·Jason W GriffithAndrew D Luster
Jul 23, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·YunJae Jung, Marc E Rothenberg
Mar 1, 2015·Gastroenterology·Niels Vande CasteeleSéverine Vermeire
May 24, 2015·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Emanuelle BellaguardaAtsushi Sakuraba
Jul 15, 2015·Journal of Biomedical Science·Eun Jeong ParkMotomu Shimaoka
Sep 2, 2015·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Michael S DonovielSarah Spiegel

❮ Previous
Next ❯

Citations

Apr 20, 2020·Molecular Nutrition & Food Research·Juan Antonio Giménez-BastidaClaus Schneider
Apr 3, 2020·Journal of Crohn's & Colitis·Christopher J TylerJesús Rivera-Nieves
Nov 5, 2020·British Journal of Pharmacology·Benjamin MisselwitzOliver Pabst
Feb 18, 2021·Journal of Cellular and Molecular Medicine·Xuewen WangHongwei Lu
Mar 6, 2021·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Juan S LasaLaurent Peyrin-Biroulet
Mar 23, 2021·Digestive Diseases and Sciences·Giorgos BamiasGerasimos Mantzaris
Feb 19, 2021·Journal of Gastroenterology and Hepatology·Katsuyoshi MatsuokaTakanori Kanai
May 22, 2021·Frontiers in Immunology·Maximilian WiendlSebastian Zundler
Jul 3, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Kai ChenYing Zhu
Dec 17, 2019·Current Pharmaceutical Biotechnology·Mehdi ZobeiriSeyed Mohammad Nabavi
Aug 8, 2021·International Journal of Molecular Sciences·Juan Antonio Giménez-BastidaJuan Carlos Espín

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.